FDA Novel Switch Meeting Shows Gulf Between Interests
This article was originally published in The Pink Sheet Daily
Drug manufacturers and physicians are at odds with the pharmacy industry’s expectations for the role pharmacists will have in distributing novel switches. At an FDA public hearing, CDER Director Janet Woodcock says the agency expects to “extend the concept of self-diagnosis and self-treatment to additional drugs.”
You may also be interested in...
BioMedican is ready to produce CBG, cannabigerol, and THC-V, tetrahydrocannabivarin, through biosynthesis and plans by the end of the year to start making CBN, cannabinol, and THC-A, tetrahydrocannabinolic-acid.
Synthetics are necessary for drugs containing cannabinoids because the active ingredient must be consistent from dose to dose. Cannabinoids extracted from hemp vary from plant to plant and more widely from crop to crop, but consistency should matter for cannabinoids used as dietary ingredients, says BioMedican president Dennis O’Neill.
Revision to FDA's September 2020 guidance on assessing nitrosamine impurity risks associated with all chemically synthesized APIs and all approved drug products that contain those APIs doesn’t satisfy industry stakeholders.